Emil D. Kakkis
2018
In 2018, Emil D. Kakkis earned a total compensation of $4.8M as President and Chief Executive Officer at Ultragenyx Pharmaceutical, a 28% decrease compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $428,400 |
|---|---|
| Option Awards | $2,753,513 |
| Salary | $679,952 |
| Stock Awards | $944,385 |
| Other | $39,377 |
| Total | $4,845,627 |
Kakkis received $2.8M in option awards, accounting for 57% of the total pay in 2018.
Kakkis also received $428.4K in non-equity incentive plan, $680K in salary, $944.4K in stock awards and $39.4K in other compensation.
Rankings
In 2018, Emil D. Kakkis' compensation ranked 2,104th out of 14,244 executives tracked by ExecPay. In other words, Kakkis earned more than 85.2% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 2,104 out of 14,244 | 85th |
Division Manufacturing | 763 out of 5,765 | 87th |
Major group Chemicals And Allied Products | 255 out of 2,128 | 88th |
Industry group Drugs | 203 out of 1,817 | 89th |
Industry Pharmaceutical Preparations | 157 out of 1,391 | 89th |
Source: SEC filing on April 22, 2019.
Kakkis' colleagues
We found six more compensation records of executives who worked with Emil D. Kakkis at Ultragenyx Pharmaceutical in 2018.
2018
Wladimir Hogenhuis
Ultragenyx Pharmaceutical
Chief Operating Officer
2018
Camille Bedrosian
Ultragenyx Pharmaceutical
Chief Medical Officer
2018
Shalini Sharp
Ultragenyx Pharmaceutical
Chief Financial Officer
2018
Karah Parschauer
Ultragenyx Pharmaceutical
General Counsel
2018
Thomas Kassberg
Ultragenyx Pharmaceutical
Chief Business Officer and Executive Vice President
2018
John Pinion
Ultragenyx Pharmaceutical